What is hyaluronidase, its indications, recommended dosing, contraindications, and potential adverse effects?

Hyaluronidase Overview

Hyaluronidase is an enzyme that degrades hyaluronic acid and is primarily used in aesthetic medicine to dissolve HA fillers and manage complications, though its routine use as an adjunct to local anesthesia in dermatologic surgery lacks sufficient evidence to support a recommendation. 1

What is Hyaluronidase?

Hyaluronidase is an enzyme that breaks down hyaluronic acid by hydrolyzing HA molecules. It works by enhancing diffusion and dispersion of injected substances through tissues 2.

Primary Indications

Aesthetic Medicine (Primary Use)

• Dissolving hyaluronic acid dermal fillers for complications including:
  • Overcorrection or undesired aesthetic outcomes 3, 4
  • Vascular occlusion (most critical indication requiring immediate treatment) 5
  • Nodules and lumps 6
  • Irregular filler distribution 3
  • Excessive volume 4

As Anesthetic Adjunct (Limited Evidence)

• May be added to local infiltration anesthesia to enhance diffusion of anesthetic solution 1
• However, no recommendations for or against its use in dermatologic surgery can be made due to insufficient data 1
• Anecdotal reports suggest it may minimize tissue distortion and ease undermining, but these claims lack supporting evidence 1

Dosing Strategies

For Dissolving HA Fillers

Vascular Occlusion (Emergency)

• Early intervention within 6 hours significantly improves outcomes 5
• Higher doses correlate with better resolution rates for skin necrosis 5
• Resolution rates: 78.4% for skin necrosis, 45.2% for visual impairment 5

General Filler Dissolution

• Most commonly used concentrations: 75-150 U/mL 6
• No statistical difference in outcomes between 75 U/mL and 150 U/mL dosing 6
• Biphasic fillers dissolve more rapidly at lower concentrations compared to monophasic fillers, which require higher concentrations and longer exposure 3
• Direct injection into filler mass is more effective than surface application 3

Important Pharmacokinetic Consideration: Hyaluronidase activity diminishes within 30 minutes in biological tissues, highlighting the need for timely intervention 3

For Local Anesthesia Adjunct

• Reported dose: 7.2 IU mixed with local anesthetic 1
• Note: Benefits remain unclear and unproven in dermatologic procedures 1

Absolute Contraindication

Do not administer hyaluronidase to patients with known bee venom allergy 1

• Cross-reactivity exists between bee venom and hyaluronidase
• When allergy is in question, prick testing may be used for confirmation 1

Adverse Effects

Common (Mild)

• Local injection site reactions 2:
  • Erythema (redness)
  • Pain
  • Swelling
  • Itching

Uncommon but Serious

• Allergic reactions (urticaria or angioedema): reported in <0.1% of patients 2
• Anaphylactic-like reactions: rare, following retrobulbar block or IV injections 2
• Edema (most frequent with subcutaneous fluid administration) 2

Post-Hyaluronidase Syndrome

• Occurs in approximately 18% of patients treated for filler dissolution 6
• Manifests as facial hollowing and unwanted volume loss
• Significant predictors include:
  • Longer duration of filler in situ (P = 0.00019) 6
  • Higher total volume of filler (P = 0.000017) 6
• Not related to hyaluronidase concentration or dose used 6

Drug Interactions

Incompatible medications (do not co-administer) 2:

• Furosemide
• Benzodiazepines
• Phenytoin
• Dopamine
• Alpha agonists

Medications requiring higher hyaluronidase doses for equivalent effect 2:

• Salicylates (e.g., aspirin)
• Steroids (e.g., cortisone, estrogens)
• Antihistamines

Clinical Pearls and Pitfalls

Critical Safety Points

1. Always screen for bee sting allergy before administration - this is the most important contraindication 1
2. Hyaluronidase enhances adverse reactions of co-administered drugs 2
3. For vascular occlusion, time is critical - intervene within 6 hours 5

Practical Considerations

• Mixing with local anesthesia is safe but benefits are unproven in dermatologic surgery 1
• When dissolving fillers, inform patients with longer filler history and higher volumes about increased risk of post-hyaluronidase syndrome 6
• Multiple treatments may be necessary for monophasic fillers 3
• 24% of patients require additional hyaluronidase treatment for insufficient initial response 6

Evidence Limitations

The American Academy of Dermatology guidelines explicitly state that randomized trials evaluating hyaluronidase added to local anesthesia are needed, and no recommendations for or against its use in dermatologic surgery can be made 1. This contrasts with its well-established role in aesthetic medicine for managing HA filler complications, where evidence is more robust 3, 4, 7, 8, 5, 9.